The following discussion of our financial condition and results of operations
should be read in conjunction with our consolidated financial statements and the
related notes included elsewhere in this filing. The discussion contains
forward-looking statements that involve known and unknown risks and
uncertainties, including those set forth under Part I, Item 1A."Risk Factors" of
this Form 10-K. The following discussion and analysis does not include certain
items related to the year ended December 31, 2017, including year-to-year
comparisons between the year ended December 31, 2018 and the year ended December
31, 2017. For a comparison of our results of operations for the fiscal years
ended December 31, 2018 and December 31, 2017, see Item 7. Management's
Discussion and Analysis of Financial Condition and Results of Operations of our
Annual Report on Form 10-K for the year ended December 31, 2018, filed with the
SEC on February 19, 2019.

                               EXECUTIVE OVERVIEW
General

We are a leading multi-national healthcare enterprise that is committed to helping people live healthier lives. We take a local approach - with local brands and local teams - to provide fully integrated, high-quality, and cost-effective services to government-sponsored and commercial healthcare programs, focusing on under-insured and uninsured individuals.



Results of operations depend on our ability to manage expenses associated with
health benefits (including estimated costs incurred) and selling, general and
administrative (SG&A) costs. We measure operating performance based upon two key
ratios. The health benefits ratio (HBR) represents medical costs as a percentage
of premium revenues, excluding premium tax and health insurer fee revenues that
are separately billed, and reflects the direct relationship between the premiums
received and the medical services provided. The SG&A expense ratio represents
SG&A costs as a percentage of premium and service revenues, excluding premium
tax and health insurer fee revenues that are separately billed.

Our insurance subsidiaries are subject to the Affordable Care Act annual health
insurer fee (HIF), absent a HIF moratorium. The Affordable Care Act (ACA)
imposed the HIF in 2018, however the HIF was suspended in 2019. In 2018, we
recognized revenue for reimbursement of the HIF, including the "gross-up" to
reflect the non-deductibility of the HIF. Collectively, this revenue is recorded
as premium tax and health insurer fee revenue in the Consolidated Statements of
Operations. For certain products, premium taxes, state assessments and the HIF
are not pass-through payments and are recorded as premium revenue and premium
tax expense or health insurer fee expense in the Consolidated Statements of
Operations. Due to the size of the HIF fee, one of the primary drivers of the
year-over-year variances discussed throughout this section is related to the
moratorium in 2019.

WellCare Acquisition

On January 23, 2020, we acquired all of the issued and outstanding shares of
WellCare Health Plans, Inc. (WellCare) (the WellCare Acquisition). The
transaction is valued at approximately $19.6 billion, including the assumption
of $1.95 billion of outstanding debt. Consideration for the acquisition
consisted of Centene common shares valued at $11.4 billion (based on Centene's
stock price of $66.76), $6.08 billion in cash, and $95 million related to the
fair value of replacement equity awards associated with pre-combination service.
Each WellCare share was converted into 3.38 of a validly issued, fully paid,
non-assessable shares of Centene common stock and $120.00 in cash. In total, 171
million shares of Centene common stock were issued to the WellCare stockholders.
The cash portion of the acquisition consideration was funded through the
issuance of long-term debt in December 2019. We issued approximately $1.0
billion 4.75% Senior Notes due 2025 (the Additional 2025 Notes), $2.5 billion
4.25% Senior Notes due 2027 (the 2027 Notes), and $3.5 billion 4.625% Senior
Notes due 2029 (the 2029 Notes). The net proceeds of the 2027 Notes and the 2029
Notes and a portion of the net proceeds of the Additional 2025 Notes were used
to finance the cash consideration.

The WellCare Acquisition brings a high-quality Medicare platform and further
extends our robust Medicaid offerings. The combination enables us to provide
access to more comprehensive and differentiated solutions across more markets
with a continued focus on affordable, high-quality, culturally-sensitive
healthcare services.

Immediately prior to the closing of the WellCare Acquisition, Anthem, Inc.
acquired WellCare's Missouri Medicaid health plan, a WellCare Missouri Medicare
Advantage health plan, and WellCare's Nebraska Medicaid health plan. CVS Health
Corporation acquired portions of Centene's Illinois Medicaid and Medicare
Advantage health plans as part of previously announced divestiture agreements.


                                       38

--------------------------------------------------------------------------------


  Table of Contents


Fidelis Care Acquisition

On July 1, 2018, we acquired substantially all of the assets of New York State
Catholic Health Plan, Inc., d/b/a Fidelis Care New York (Fidelis Care) for
approximately $3.6 billion of cash consideration, including a working capital
adjustment. Due to the size of the acquisition, one of the primary drivers of
the year-over-year variances discussed throughout this section for the year
ended December 31, 2019, is related to the acquisition of Fidelis Care.

International



In Spain, in June 2019, we purchased an additional 40% ownership in Ribera Salud
from Banco Sabadell for $54 million, bringing our total ownership to 90%. In
December 2019, our Spanish subsidiary, Ribera Salud, acquired 93% of Hospital
Povisa, S.A., a private hospital in the Vigo region of Spain.

Regulatory Trends and Uncertainties

The United States government, politicians, and healthcare experts continue to
discuss and debate various elements of the United States healthcare payment
model. From the constitutionality of the Affordable Care Act, to Medicare for
All (single payer), to pharmacy pricing structures, all areas of healthcare are
being challenged to assure adequate healthcare is delivered to all segments of
the population.

During this time of deliberation, we remain focused on the promise of delivering
access to high quality, affordable healthcare to all of our members and believe
we are well positioned to meet the needs of the changing healthcare landscape.
We have more than three decades of experience, spanning six presidents from both
sides of the aisle, in delivering high-quality healthcare services on behalf of
states and the federal government to under-insured and uninsured families,
commercial organizations and military families. This expertise has allowed us to
deliver cost effective services to our government sponsors and our members.
While healthcare experts maintain focus on personalized healthcare technology,
we continue to make strategic decisions to accelerate development of new
software platforms and analytical capabilities. We continue to believe we have
both the capacity and capability to successfully navigate industry changes to
the benefit of our members, customers and shareholders.

For additional information regarding regulatory trends and uncertainties, see Part I, Item 1 "Business - Regulation" and Item 1A, "Risk Factors."

2019 Highlights

Our financial performance for 2019 is summarized as follows:



•         Year-end managed care membership of 15.2 million, an increase of 1.1
          million members, or 8% over 2018.


• Total revenues of $74.6 billion, representing 24% growth year-over-year.

• HBR of 87.3% for 2019, compared to 85.9% for 2018.

• SG&A expense ratio of 9.3% for 2019, compared to 10.7% for 2018.

• Adjusted SG&A expense ratio of 9.2% for 2019, compared to 10.0% for 2018.

• Diluted EPS of $3.14 for 2019, compared to $2.26 for 2018.

• Adjusted Diluted EPS of $4.42 for 2019, compared to $3.54 for 2018.

• Operating cash flows of $1.5 billion, or 1.1 times net earnings, for 2019.






                                       39

--------------------------------------------------------------------------------

Table of Contents

A reconciliation from GAAP diluted EPS to Adjusted Diluted EPS is highlighted below, and additional detail is provided above under the heading "Non-GAAP Financial Presentation":


                                                 Year Ended December 31,
                                                      2019               2018

GAAP diluted EPS attributable to Centene   $        3.14                $ 

2.26


Amortization of acquired intangible assets          0.47                  

0.41


Acquisition related expenses                        0.19                  0.81
Other adjustments (1)                               0.62                  0.06
Adjusted Diluted EPS                       $        4.42                $ 3.54

(1) Other adjustments include the following items:




•            2019 - non-cash goodwill and intangible asset impairment of $271
             million or $0.57 per diluted share, net of an income tax benefit of
             $0.08 and debt extinguishment costs of $30 million or $0.05 per
             diluted share, net of an income tax benefit of $0.02; and


•            2018 - the impact of retroactive changes to the California minimum
             medical loss ratio (MLR) of $30 million of expense or $0.06 per
             diluted share, net of an income tax benefit of $0.02.

The 2018 results include the following items, which in the aggregate had no net effect on diluted EPS:

• During the year ended December 31, 2018, we received 2014-2017 cost

reconciliation information related to the California Medicaid in-home


       support services (IHSS) program, which ended December 31, 2017. As a
       result, our 2018 results include an estimated pre-tax benefit of $140
       million related to the IHSS program reconciliation.


• On September 30, 2018, our contract to provide health care coordination

services to the U.S. Department of Veterans Affairs under the

Patient-Centered Community Care and Veterans Choice Programs expired. In

connection with the conclusion of the contract, during the year ended

December 31, 2018, we recorded a pre-tax charge of $110 million for

negotiated settlements and severance costs. We will continue to provide


       close out and transition services through 2021.


• During the year ended December 31, 2018, we recorded pre-tax expense of

$30 million associated with a contribution commitment to our charitable


       foundation.



The following items contributed to our revenue and membership growth in 2019:

Arizona. In October 2018, our Arizona subsidiary, Health Net Access, began


       providing physical and behavioral health care services under a new
       integrated contract through the Arizona Health Care Cost Containment
       System Complete Care program in the Central and Southern regions.


Arkansas. In February 2018, our Arkansas subsidiary, Arkansas Total Care,

began managing a Medicaid special needs population comprised of people


       with high behavioral health needs and individuals with
       developmental/intellectual disabilities. Arkansas Total Care assumed
       full-risk on this population in March 2019.


• CMG. In March 2018, we completed the acquisition of CMG, an at-risk

primary care provider serving Medicaid, Medicare Advantage, and Health

Insurance Marketplace patients in Florida.


• Correctional. In July 2019, Centurion began operating under a contract to

provide comprehensive healthcare services to inmates housed in Arizona's

state prison system, and also began operating under a re-awarded contract

to continue the provision of mental and dental health services to the

Georgia Department of Correction's state prison facilities. In February


       2019, Centurion began operating under a new contract to provide
       comprehensive healthcare services to detainees of the Metropolitan
       Detention Center located in Albuquerque, New Mexico. In December 2018,

Centurion began operating under a new contract to provide comprehensive

healthcare services to detainees of Volusia County detention facilities

located near Daytona, Florida. In July 2018, Centurion began operating

under a contract to provide healthcare services for correctional

facilities in Pima County, Arizona. In April 2018, we completed the

acquisition of MHM, a national provider of healthcare and staffing

services to correctional systems and other government agencies. Under the

terms of the agreement, Centene also acquired the remaining 49% ownership

of Centurion, the correctional healthcare services joint venture between

Centene and MHM. In addition, during 2018, Centurion's contracts for

correctional facilities were reprocured in New Hampshire and Tennessee.





                                       40

--------------------------------------------------------------------------------

Table of Contents

Fidelis Care. In July 2018, we completed the acquisition of substantially

all of the assets of Fidelis Care for $3.6 billion of cash consideration,


       making Fidelis Care Centene's health plan in New York State.


Florida. In December 2018, our Florida subsidiary, Sunshine Health, began

providing physical and behavioral healthcare services through Florida's

Statewide Medicaid Managed Care Program under its new five year contract


       which was implemented for all 11 regions by February 2019.


Health Insurance Marketplace. In January 2019, we expanded our offerings

in the 2019 Health Insurance Marketplace. We entered Pennsylvania, North

Carolina, South Carolina, and Tennessee, and expanded our footprint in six

existing markets: Florida, Georgia, Indiana, Kansas, Missouri, and Texas.

In January 2018, we expanded our offerings in the 2018 Health Insurance


       Marketplace. We entered Kansas, Missouri and Nevada, and expanded our
       footprint in the following six existing markets: Florida, Georgia,
       Indiana, Ohio, Texas, and Washington.


Health Net Federal Services. In January 2018, our subsidiary, Health Net

Federal Services, began operating under the TRICARE West Region contract

to provide administrative services to Military Health System eligible


       beneficiaries.



•      HealthSmart. In May 2019, we acquired HealthSmart, a third party

administrator providing customizable and scalable health plan solutions

for self-funded employers, universities and colleges, and Native American

Tribal Enterprises. Services include plan administration, care management


       and wellness programs, network, casualty claim, and pharmacy benefit
       solutions.


Illinois. In January 2018, our Illinois subsidiary, IlliniCare Health,


       began operating under a state-wide contract for the Medicaid Managed Care
       Program. Implementation dates varied by region and the contract was fully
       implemented statewide in April 2018.



•      Interpreta. In March 2018, we acquired an additional 61% ownership in

Interpreta, a clinical and genomics data analytics business, bringing our


       total ownership to 80%.



•      Iowa. In July 2019, our Iowa subsidiary, Iowa Total Care, Inc., began

operating under a new statewide contract for the IA Health Link Program.

Kansas. In January 2019, our Kansas subsidiary, Sunflower Health Plan,
       continued providing managed care services to KanCare beneficiaries
       statewide under a new contract.


• Medicare. In January 2019, we expanded our Medicare offerings, entering

Illinois and New Mexico. In January 2018, we expanded our offerings in

Medicare. We entered Arkansas, Indiana, Kansas, Louisiana, Missouri,

Pennsylvania, South Carolina, and Washington and expanded our footprint in

Ohio.


New Hampshire. In September 2019, our New Hampshire subsidiary, NH Healthy


       Families, began operating under a new five-year contract to continue to
       provide service to Medicaid enrollees statewide.



•      New Mexico. In January 2019, our New Mexico subsidiary, Western Sky
       Community Care, began operating under a new statewide contract in New
       Mexico for the Centennial Care 2.0 Program.


Pennsylvania. In January 2018, our Pennsylvania subsidiary, Pennsylvania

Health and Wellness, began serving enrollees in the Community

HealthChoices program as part of the statewide contract that was fully


       implemented in January 2020.


• QualChoice. In April 2019, we completed the acquisition of QCA Health

Plan, Inc. and QualChoice Life and Health Insurance Company, Inc. The

acquisition expands our footprint in Arkansas by adding additional members


       primarily through commercial products.


Spain. In December 2019, our Spanish subsidiary, Ribera Salud, acquired

93% of Hospital Povisa, S.A., a private hospital in the Vigo region of

Spain. In June 2019, Primero Salud, acquired additional ownership in

Ribera Salud, increasing our ownership in the Spanish healthcare company

from 50% to 90%. In December 2018, Primero Salud acquired 89% of Torrejón


       Salud, a public-private partnership in the Community of Madrid.




                                       41

--------------------------------------------------------------------------------

Table of Contents

Washington. In January 2018, our Washington State subsidiary, Coordinated

Care of Washington, began providing managed care services to Apple

Health's Fully Integrated Managed Care beneficiaries in the North Central


       Region. This integration continued into 2019 with the addition of the
       Greater Columbia, King and Pierce Regions going live January 2019,
       followed by the North Sound Region in July 2019.


• In addition, we realized the full year benefit in 2019 of acquisitions,

investments, and business commenced during 2018.

The growth items listed above were partially offset by the following items:

• Beginning January 1, 2019, Health Net of Arizona, Inc. began discontinuing

and non-renewing all of its Employer Group plans for small and large

business groups in Arizona. The effective date of coverage termination for

existing groups is dependent on remaining renewals; however, coverage is


       no longer provided to any group policyholders and/or members as of
       December 31, 2019.


• In 2018, we were successful in reprocuring our contracts in Mississippi,

New Hampshire and Washington. However, the Medicaid programs were expanded


       to include additional insurers, which has reduced our market share.

• We no longer serve Medicaid and correctional members in Massachusetts.

• Effective October 2018, we no longer provide health care coordination


       services to veterans under the Patient-Centered Community Care and
       Veterans Choice Programs.


• Beginning in January 2018, the State of California no longer includes

costs for IHSS in its Medicaid contracts.

We expect the following items to contribute to our revenue or future growth potential:

• We expect to realize the full year benefit in 2020 of acquisitions,


       investments, and business commenced during 2019, as discussed above.


• In February 2020, we began operating in Illinois under the first phase of

an expanded contract for the Medicaid Managed Care Program. The expanded


       contract includes children who are in need through the Department of
       Children and Family Services/Youth Care by the Illinois Department of
       Healthcare and Family Services and Foster Care.


• In January 2020, we completed the WellCare Acquisition. The WellCare

Acquisition brings a high-quality Medicare platform and further extends

our robust Medicaid offerings. The WellCare Acquisition is a key part of

our growth as we become one of the nation's largest sponsors of government

health coverage. The transaction is valued at approximately $19.6 billion,


       including the assumption of $1.95 billion of outstanding debt.



•      In January 2020, we expanded our offerings in the Health Insurance

Marketplace in ten existing markets: Arizona, Florida, Georgia, Kansas,

North Carolina, Ohio, South Carolina, Tennessee, Texas and Washington.

• In January 2020, our Louisiana subsidiary, Louisiana Healthcare

Connections, began operating under a one-year emergency contract extension

in response to protested contract awards. Louisiana's state procurement

officer overturned the Louisiana Department of Health's plan to award

Medicaid contracts to four health plans, excluding our Louisiana

subsidiary. According to the chief procurement officer, the state health


       department failed to follow state law or its own evaluation and bid
       guidelines in its award.


• In November 2019, our Texas subsidiary, Superior HealthPlan, was awarded

by the Texas Health and Human Services Commission a contract to continue

to provide healthcare services to enrollees in the state's STAR+PLUS

program. The contract is expected to be effective on September 1, 2020,

and will allow Superior HealthPlan to offer coverage in two new service


       areas, for a total of nine service areas.


• In October 2019, our North Carolina joint venture, Carolina Complete

Health, was awarded an additional service area to provide Medicaid managed

care services in Region 4. With the addition of this new Region, Carolina


       Complete Health will provide Medicaid managed care services in three
       contiguous regions: Region 3, 4 and 5. The new three-year contract is
       expected to commence in the second half of 2020.




                                       42

--------------------------------------------------------------------------------

Table of Contents

• In October 2018, CMS published updated Medicare Star quality ratings for

the 2019 rating year. Our Star ratings returned to a 4.0 Star parent

rating. The 2019 rating year will positively affect quality bonus payments

for Medicare Advantage plans in 2020.

The future growth items listed above are partially offset by the following items:

• In January 2020, in connection with the WellCare Acquisition, we completed

the divestiture of certain products in our Illinois health plan, including


       the Medicaid and Medicare Advantage lines of business.



•      Effective December 2019, we no longer serve under the state-wide
       correctional contract in New Mexico.


• In October 2019, CMS published updated Medicare Star quality ratings for

the 2020 rating year. Approximately 46% of our Medicare members are in a 4

star or above plan for the 2021 bonus year, compared to approximately 86%

for the 2020 bonus year. Our quality bonus and rebates may be negatively


       impacted in 2021.


• In July 2019, our Oregon subsidiary, Trillium Community Health Plan, was

notified by the Oregon Health Authority (OHA) of its intent to award

Trillium Community Health Plan an expanded contract to serve as a

coordinated care organization for six counties in the state; however, an


       additional competitor was added to Lane County. As a result, our
       membership is expected to decrease. Pending successful completion of OHA's
       readiness review and additional contract negotiations, the contract is
       expected to begin July 2020.



                                   MEMBERSHIP

From December 31, 2018 to December 31, 2019, we increased our managed care
membership by 1.1 million, or 8%. The following table sets forth our membership
by line of business:
                                                          December 31
                                                  2019                  2018
Medicaid:
TANF, CHIP & Foster Care                           7,528,700             7,356,200
ABD & LTSS                                         1,043,500             1,002,100
Behavioral Health                                     66,500                36,500
Total Medicaid                                     8,638,700             8,394,800
Commercial                                         2,331,100             1,978,000
Medicare (1)                                         404,500               416,900
International                                        599,800               151,600
Correctional                                         180,000               151,300
Total at-risk membership                          12,154,100            11,092,600
TRICARE eligibles                                  2,860,700             2,858,900
Non-risk membership                                  227,000               219,700
Total                                             15,241,800            14,171,200

(1) Membership includes Medicare Advantage, Medicare Supplement, Special Needs Plans, and Medicare-Medicaid Plans (MMP).


                                       43

--------------------------------------------------------------------------------

Table of Contents

The following table sets forth additional membership statistics, which are included in the membership information above:


                                                            December 31
                                                    2019                    2018
Dual-eligible (2)                                        639,200               598,200
Health Insurance Marketplace                           1,805,200             1,459,100
Medicaid Expansion                                     1,346,700             1,262,100

(2) Membership includes dual-eligible ABD & LTSS and dual-eligible Medicare membership in the table above.

From December 31, 2018 to December 31, 2019, our membership increased as a result of: • membership growth in our Health Insurance Marketplace business;

• international acquisitions; and

• expansions and new programs in many of our states.


                                       44

--------------------------------------------------------------------------------


  Table of Contents



                             RESULTS OF OPERATIONS

The following discussion and analysis is based on our Consolidated Statements of
Operations, which reflect our results of operations for years ended December 31,
2019, and 2018, respectively, prepared in accordance with generally accepted
accounting principles in the United States ($ in millions, except per share data
in dollars):
                                             2019              2018         % Change 2018-2019
Premium                                 $      67,439     $      53,629               26  %
Service                                         2,925             2,806                4  %
Premium and service revenues                   70,364            56,435               25  %
Premium tax and health insurer fee              4,275             3,681               16  %
Total revenues                                 74,639            60,116               24  %
Medical costs                                  58,862            46,057               28  %
Cost of services                                2,465             2,386                3  %
Selling, general and administrative
expenses                                        6,533             6,043                8  %
Amortization of acquired intangible
assets                                            258               211               22  %
Premium tax expense                             4,469             3,252               37  %
Health insurer fee expense                          -               709             n.m.
Goodwill and intangible impairment                271                 -             n.m.
Earnings from operations                        1,781             1,458               22  %
Other income (expense):
Investment and other income                       443               253               75  %
Debt extinguishment costs                         (30 )               -             n.m.
Interest expense                                 (412 )            (343 )            (20 )%
  Earnings from operations, before
income tax expense                              1,782             1,368               30  %
Income tax expense                                473               474                -  %
  Net earnings                                  1,309               894               46  %
Loss attributable to noncontrolling
interests                                          12                 6              100  %
Net earnings attributable to Centene
Corporation                             $       1,321     $         900     

47 %



Diluted earnings per common share
attributable to Centene Corporation:    $        3.14     $        2.26               39  %


n.m.: not meaningful

Year Ended December 31, 2019 Compared to Year Ended December 31, 2018

Total Revenues

The following table sets forth supplemental revenue information for the year ended December 31, ($ in millions):



                                                                                % Change
                                   2019                    2018                2018-2019
Medicaid                  $             50,404     $           39,427                   28 %
Commercial                              14,747                 12,391                   19 %
Medicare (1)                             5,675                  5,093                   11 %
Other                                    3,813                  3,205                   19 %
Total Revenues            $             74,639     $           60,116                   24 %

(1) Medicare includes Medicare Advantage, Medicare Supplement, Special Needs Plans, and MMP.





                                       45

--------------------------------------------------------------------------------

Table of Contents





Total revenues increased 24% in the year ended December 31, 2019, over the
corresponding period in 2018, primarily due to the acquisition of Fidelis Care,
growth in the Health Insurance Marketplace business, and expansions and new
programs in many of our states in 2018 and 2019, particularly Arkansas,
Illinois, Iowa, New Mexico and Pennsylvania. These increases were partially
offset by the health insurer fee moratorium in 2019. Total revenues also
increased due to at-risk, state directed and pass through payments of
approximately $825 million from the State of California and pass through
payments of approximately $531 million from the State of New York. During the
twelve months ended December 31, 2019, we received Medicaid premium rate
adjustments which yielded a net 2% composite change across all of our markets.

Operating Expenses

Medical Costs

Results of operations depend on our ability to manage expenses associated with
health benefits and to accurately estimate costs incurred. The HBR represents
medical costs as a percentage of premium revenues, excluding premium tax and
health insurer fee revenues that are separately billed, and reflects the direct
relationship between the premiums received and the medical services provided.

The HBR for the year ended December 31, 2019 was 87.3%, an increase of 140 basis
points over the comparable period in 2018. The HBR increase was primarily
attributable to the Health Insurance Marketplace business where margins have
normalized, as expected, from the favorable performance in 2018 and the health
insurer fee moratorium. Also, the 2018 HBR benefited from the recognition of the
IHSS program reconciliation.

Cost of Services



Cost of services increased by $79 million in the year ended December 31, 2019,
compared to the corresponding period in 2018. The cost of service increase is
primarily attributable to the operations of newly acquired businesses, partially
offset by the Veterans Affairs contract expiration, effective October 2018.

The cost of service ratio for the year ended December 31, 2019 was 84.3%, compared to 85.0% in 2018. The decrease in the cost of service ratio was primarily due to the Veterans Affairs contract expiration.

Selling, General and Administrative Expenses



SG&A increased by $490 million in the year ended December 31, 2019, compared to
the corresponding period in 2018. The SG&A increase was primarily attributable
to the acquisition of Fidelis Care, expansions, new programs, and growth in many
of our states in 2019, including growth in the Health Insurance Marketplace
business, partially offset by a decrease in acquisition related costs.

The SG&A expense ratio was 9.3% for the year ended December 31, 2019, compared
to 10.7% for the year ended December 31, 2018. The year-over-year decrease was
primarily due to $336 million of lower acquisition related expenses. The
Adjusted SG&A expense ratio was 9.2% for the year ended December 31, 2019,
compared to 10.0% for the year ended December 31, 2018. Both ratios decreased
due to the acquisition of Fidelis Care, which operates at a lower SG&A expense
ratio, the Veterans Affairs contract expiration in 2018, and lower variable
compensation costs in 2019.

Health Insurer Fee Expense



As a result of the health insurer fee moratorium, which suspended the health
insurance provider fee for the 2019 calendar year, we did not record HIF expense
for the year ended December 31, 2019, compared to $709 million for the year
ended December 31, 2018.

Goodwill and Intangible Impairment



In 2019, we recorded $271 million, or $0.57 per diluted share, of non-cash
goodwill and intangible asset impairment. Substantially all of the impairment is
associated with our USMM physician home health business and was identified as
part of our third quarter review procedures, which included an analysis of new
information related to our shared savings demonstration programs, slower than
expected penetration of the physician home health business model into our
Medicaid population, and the related impact to revised forecasts. The business
continues to generate positive cash flows and plays an important role in care
management; however, it has fallen short of our overall performance
expectations.


                                       46

--------------------------------------------------------------------------------


  Table of Contents


Other Income (Expense)

The following table summarizes the components of other income (expense) for the year ended December 31, ($ in millions):


                             2019      2018
Investment and other income $ 443     $ 253
Debt extinguishment costs     (30 )       -
Interest expense             (412 )    (343 )

Other income (expense), net $ 1 $ (90 )





Investment and other Income. Investment and other income increased by $190
million for year ended December 31, 2019 compared to 2018. The increase in
investment income in 2019 reflects higher investment balances over 2018,
including the proceeds of our $7.0 billion senior note issuance related to the
planned financing for the cash consideration for the WellCare Acquisition and
the impact of higher investment balances as a result of the Fidelis Care
acquisition. The increase also reflects higher interest rates, the Ribera Salud
acquisition gain of $16 million, and improved performance associated with our
deferred compensation investment portfolio, which fluctuates with its underlying
investments. The earnings from our deferred compensation portfolio were
substantially offset by increases in deferred compensation expense, recorded in
SG&A expense.

Debt Extinguishment costs. In October 2019, we redeemed the outstanding
principal balance on the $1,400 million 5.625% Senior Notes due February 15,
2021, plus applicable premium for early redemption and accrued and unpaid
interest through the redemption date. We recognized a pre-tax loss on
extinguishment of $30 million on the redemption of the $1,400 million 5.625%
Senior Notes, including the call premium, the write-off of unamortized debt
issuance costs and a loss on the termination of the $600 million interest rate
swap agreement associated with the notes.

Interest expense. Interest expense increased by $69 million in the year ended
December 31, 2019, compared to the corresponding period in 2018. The increase is
driven by a net increase in borrowings related to the issuance of an additional
$7.0 billion in senior notes in December 2019, intended primarily to finance the
cash consideration of the WellCare Acquisition, and increased borrowings in May
2018 related to the financing of the Fidelis Care acquisition.

The net impact of the $7.0 billion senior notes issued in preparation of the WellCare acquisition was approximately $13 million.

Income Tax Expense



For the year ended December 31, 2019, we recorded income tax expense of $473
million on pre-tax earnings of $1.8 billion, or an effective tax rate of 26.5%,
which reflects the impact of the health insurer fee moratorium, partially offset
by the non-deductibility of a portion of our non-cash goodwill and intangible
impairment recorded in the third quarter of 2019. For the year ended December
31, 2018, we recorded income tax expense of $474 million on pre-tax earnings of
$1.4 billion, or an effective tax rate of 34.6%, which reflects the impact of
the non-deductibility of the health insurer fee.

Segment Results

The following table summarizes our consolidated operating results by segment for the year ended December 31, ($ in millions):


                                                    % Change
                            2019         2018      2018-2019
Total Revenues
Managed Care             $ 71,379     $ 57,099         25  %
Specialty Services         13,781       12,506         10  %
Eliminations              (10,521 )     (9,489 )      (11 )%
Consolidated Total       $ 74,639     $ 60,116         24  %
Earnings from Operations
Managed Care             $  1,806     $  1,310         38  %
Specialty Services            (25 )        148       (117 )%
Consolidated Total       $  1,781     $  1,458         22  %




                                       47

--------------------------------------------------------------------------------


  Table of Contents


Managed Care

Total revenues increased 25% in the year ended December 31, 2019, compared to
the corresponding period in 2018, primarily due to the acquisition of Fidelis
Care, growth in the Health Insurance Marketplace business, and expansions and
new programs in many of our states in 2018 and 2019, particularly Arkansas,
Illinois, Iowa, New Mexico and Pennsylvania. These increases were partially
offset by the health insurer fee moratorium in 2019. Total revenues also
increased due to at-risk, state directed and pass through payments of
approximately $825 million from the State of California and pass through
payments of approximately $531 million from the State of New York. Earnings from
operations increased $496 million between years primarily as a result of the
acquisition of Fidelis Care and lower acquisition related expenses, partially
offset by the health insurer fee moratorium in 2019.

Specialty Services



Total revenues increased 10% in the year ended December 31, 2019, compared to
the corresponding period in 2018, resulting primarily from increased services
associated with membership growth in the Managed Care segment and acquisitions,
partially offset by the previously mentioned Veterans Affairs contract
expiration.  Earnings from operations decreased $173 million between years
primarily due to the previously discussed non-cash goodwill and intangible
impairment and our transition to transparent pharmacy pricing, partially offset
by higher costs recognized in 2018 associated with our Veterans Affairs contract
expiration. The transparent pricing decrease was offset by higher earnings in
our Managed Care segment and reflects our commitment to transparency and more
closely aligns the costs of care within each segment.






                        LIQUIDITY AND CAPITAL RESOURCES

Shown below is a condensed schedule of cash flows for the years ended December
31, 2019 and 2018, used in the discussion of liquidity and capital resources ($
in millions).
                                                           Year Ended December 31,
                                                          2019                 2018

Net cash provided by operating activities $ 1,483 $

1,234


Net cash used in investing activities                       (1,532 )              (4,585 )
Net cash provided by financing activities                    6,832          

4,612


Effect of exchange rate changes on cash and cash
equivalents                                                     (2 )                   -
Net increase in cash, cash equivalents, and
restricted cash and equivalents                    $         6,781       $  

1,261

Cash Flows Provided by Operating Activities



Normal operations are funded primarily through operating cash flows and
borrowings under our credit facility. Cash flows from operating activities for
2019 were $1.5 billion, or 1.1 times net earnings, compared to $1.2 billion in
2018. The cash provided by operations in 2019 was primarily due to net earnings
and an increase in medical claims liabilities, primarily resulting from growth
in the Health Insurance Marketplace business and the commencement or expansion
of the Arkansas, Iowa, New Mexico, and Pennsylvania health plans. Operating cash
flows were partially offset by an increase in premium and trade receivables due
to the timing of payments from our state customers, as discussed below.

The cash provided by operations in 2018 was primarily due to net earnings and an
increase in medical claims liabilities, primarily resulting from growth in the
Health Insurance Marketplace business. Cash flows were partially offset by an
increase in premium and trade receivables of $1.2 billion, due to growth in the
business. Additionally, cash flows from operations were negatively affected by
the repayment of approximately $1.0 billion of Medicaid expansion rate
overpayments and Medicaid expansion minimum MLR rebates in California, which
were previously accrued.

Cash flows from operations in each year were impacted by the timing of payments
we received from our states. States may prepay the following month premium
payment, which we record as unearned revenue, or they may delay our premium
payment, which we record as a receivable. We typically receive capitation
payments monthly; however, the states in which we operate may decide to adjust
their payment schedules which could positively or negatively impact our reported
cash flows from operating activities in any given period.
                                                        Year Ended December 

31,


                                                          2019             

2018

(Increase) decrease in premium and trade receivables $ (1,076 ) $ (1,173 ) Increase (decrease) in unearned revenue

                        (9 )         

(52 ) Net increase (decrease) in operating cash flow $ (1,085 ) $ (1,225 )

Cash Flows Used in Investing Activities



Investing activities used cash of $1.5 billion for the year ended December 31,
2019 and $4.6 billion in 2018. Cash flows used in investing activities in 2019
primarily consisted of net additions to the investment portfolio of our
regulated subsidiaries (including transfers from cash and cash equivalents to
long-term investments) and capital expenditures.

We spent $730 million and $675 million in the years ended December 31, 2019 and
2018, respectively, on capital expenditures for system enhancements and market
and corporate headquarters expansions.

As of December 31, 2019, our investment portfolio consisted primarily of
fixed-income securities with a weighted average duration of 3.2 years. We had
unregulated cash and investments of $7.2 billion at December 31, 2019,
reflecting the net proceeds from our $7.0 billion senior note issuance in
advance of the closing of the WellCare Acquisition, compared to $478 million at
December 31, 2018. Unregulated cash and investments include private equity
investments and company owned life insurance contracts.

Cash flows used in investing activities in 2018 primarily consisted of the Fidelis Care and other acquisitions, the net additions to the investment portfolio of our regulated subsidiaries (including transfers from cash and cash equivalents to long-term investments), and capital expenditures.


                                       48

--------------------------------------------------------------------------------

Table of Contents

Cash Flows Provided by Financing Activities

Our financing activities provided cash of $6.8 billion in 2019, compared to providing cash of $4.6 billion in 2018. Financing activities in 2019 and 2018 are discussed below.



2019

During 2019, our net financing activities primarily related to the proceeds from
the issuance of $7.0 billion of senior notes in December 2019 in preparation of
the WellCare Acquisition.

2018

During 2018, our net financing activities primarily related to our offering of
$2.8 billion in shares of common stock, par value $0.001 per share,
approximately $1.8 billion of 5.375% senior notes at par due 2026, and
additional borrowings on our Revolving Credit Facility. Proceeds from both
offerings were used to fund the Fidelis Care acquisition which closed on July 1,
2018, to pay related fees and expenses, and for general corporate purposes,
including the repayment of outstanding indebtedness.

Liquidity Metrics



Our credit agreement, dated as of September 11, 2019, by and among Centene,
Wells Fargo Bank, National Association, as administrative agent, and the lenders
from time to time party thereto, provides for (i) a $2.0 billion unsecured
multi-currency revolving credit facility (the Revolving Credit Facility) which
includes a $300 million sub-limit for letters of credit and a $200 million
sub-limit for swingline loans and (ii) a $1.450 billion unsecured delayed-draw
term loan facility (the Term Loan Facility, together with the Revolving Credit
Facility under the credit agreement, as amended, the Company Credit Facility).
Borrowings under our Revolving Credit Facility bear interest, at our option, at
LIBOR, EURIBOR, CDOR, BBR or base rates plus, in each case, an applicable margin
based on the total debt to EBITDA ratio. Borrowings under the Term Loan Facility
bear interest, at our option, at LIBOR or base rates plus, in each case, an
applicable margin based on the total debt to EBITDA ratio. Our Revolving Credit
Facility will mature on May 7, 2024. The Term Loan Facility will mature on
September 11, 2022.

In October 2019, we borrowed $1,450 million under the Term Loan Facility. We
also redeemed the outstanding principal balance on the $1,400
million 5.625% Senior Notes due February 15, 2021, plus applicable premium for
early redemption and accrued and unpaid interest through the redemption date. We
recognized a loss on extinguishment of debt of $30 million on the redemption of
the notes in the fourth quarter of 2019, including the call premium, the
write-off of unamortized debt issuance costs, and a loss on the termination of
the $600 million interest rate swap agreement associated with the note.

In October 2019, our Board of Directors approved a $500 million increase to our
Company's stock repurchase program. Under the increased stock repurchase
program, we will have flexibility to repurchase shares or pay down debt with the
proceeds from divestitures related to the WellCare acquisition.

In December 2019, in connection with the planned financing of the WellCare
Acquisition, we issued approximately $1.0 billion 4.75% Senior Notes due 2025
(the Additional 2025 Notes), $2.5 billion 4.25% Senior Notes due 2027 (the 2027
Notes), and $3.5 billion 4.625% Senior Notes due 2029 (the 2029 Notes). The net
proceeds of the 2027 Notes and the 2029 Notes and a portion of the net proceeds
of the Additional 2025 Notes were used to finance the cash consideration.

The credit agreement underlying our Revolving Credit Facility and Term Loan
Facility contains non-financial and financial covenants, including requirements
of minimum fixed charge coverage ratios and maximum debt-to-EBITDA ratios. We
are required to not exceed a maximum debt-to-EBITDA ratio of 3.5 to 1.0. As of
December 31, 2019, we had $93 million in borrowings outstanding under our
Revolving Credit Facility and $1,450 million in borrowings outstanding under our
Term Loan Facility and we were in compliance with all covenants. As of
December 31, 2019, there were no limitations on the availability under the
Revolving Credit Facility as a result of the debt-to-EBITDA ratio.

We have a $200 million non-recourse construction loan to fund the expansion of
our corporate headquarters. The loan bears interest based on the one month LIBOR
plus 2.70% and matures in April 2021 with an optional one-year extension. The
agreement contains financial and non-financial covenants aligning with our
Company Credit Facility. We have guaranteed completion of the construction
project associated with the loan. As of December 31, 2019, we had $140 million
of borrowings outstanding under the loan.


                                       49

--------------------------------------------------------------------------------

Table of Contents




We had outstanding letters of credit of $68 million as of December 31, 2019,
which were not part of our Revolving Credit Facility. We also had letters of
credit for $27 million (valued at the December 31, 2019 conversion rate), or €24
million, representing our proportional share of the letters of credit issued to
support Ribera Salud's outstanding debt, which are a part of the Revolving
Credit Facility. Collectively, the letters of credit bore weighted interest of
0.9% as of December 31, 2019. In addition, we had outstanding surety bonds of
$611 million as of December 31, 2019.

The indentures governing our various maturities of senior notes contain restrictive covenants of Centene Corporation. As of December 31, 2019, we were in compliance with all covenants.



At December 31, 2019, we had working capital, defined as current assets less
current liabilities, of $7,391 million, compared to $27 million at December 31,
2018, reflecting the net proceeds from our $7.0 billion senior note issuance in
advance of the closing of the WellCare Acquisition. We manage our short-term and
long-term investments with the goal of ensuring that a sufficient portion is
held in investments that are highly liquid and can be sold to fund short-term
requirements as needed.

At December 31, 2019, our debt to capital ratio, defined as total debt divided
by the sum of total debt and total equity, was 52.0%, compared to 37.8% at
December 31, 2018. Excluding $194 million of non-recourse debt, our debt to
capital ratio was 51.7% as of December 31, 2019, compared to 37.4% at
December 31, 2018. At December 31, 2019, excluding non-recourse debt and the
senior notes issued to fund the WellCare Acquisition in advance of closing, our
debt to capital was 34.3%. We utilize the debt to capital ratio as a measure,
among others, of our leverage and financial flexibility.

We have a stock repurchase program authorizing us to repurchase common stock
from time to time on the open market or through privately negotiated
transactions. Based on the closing stock price of $66.76 on December 31, 2019,
we have 14.2 million available shares remaining under the program for
repurchases as of December 31, 2019. No duration has been placed on the
repurchase program. We reserve the right to discontinue the repurchase program
at any time. We did not make any repurchases under this plan during 2019 or
2018.

During the year ended December 31, 2019 and 2018, we received dividends of $713 million and $475 million, respectively, from our regulated subsidiaries.

2020 Expectations



During 2020, we do not expect to make any material net capital contributions to
our insurance subsidiaries and expect to spend approximately $775 million in
additional capital expenditures primarily associated with system enhancements
and market and corporate headquarters expansions. These amounts exclude any
contributions or capital expenditures related to our newly acquired WellCare
subsidiaries. Capital contributions and capital expenditures are expected to be
funded by unregulated cash flow generation and borrowings on our Revolving
Credit Facility and construction loan. However, from time to time we may elect
to raise additional funds for these and other purposes, either through issuance
of debt or equity, the sale of investment securities or otherwise, as
appropriate. In addition, we may strategically pursue refinancing opportunities
to extend maturities and/or improve terms of our indebtedness if we believe such
opportunities are favorable to us.

In February 2020, we issued $2,000 million 3.375% Senior Notes due 2030 (the
2030 Notes). We intend to use the net proceeds from the 2030 Notes, together
with available cash on hand, to redeem our outstanding $1,000 million 4.75%
Senior Notes due 2022 and outstanding $1,000 million 6.125% Senior Notes due
2024, including all premiums, accrued interest and costs and expenses related to
the redemption. In connection with this refinancing, we terminated the remaining
$2,100 million interest rate swap agreements.

On January 23, 2020, we acquired all of the issued and outstanding shares of
WellCare Health Plans, Inc. (WellCare, and such acquisition, the WellCare
Acquisition). Total consideration for the acquisition was $17.6 billion,
consisting of Centene common shares valued at $11.4 billion (based on Centene's
stock price of $66.76), $6.1 billion in cash, and $95 million related to the
fair value adjustment to stock based compensation associated with
pre-combination service. Each WellCare share was converted into 3.38 of a
validly issued, fully paid, non-assessable shares of Centene common stock
and $120.00 in cash. In total, 171,225 thousand shares of Centene common stock
were issued to the WellCare stockholders. The cash portion of the acquisition
consideration was funded through the issuance of long-term debt in December
2019. We issued approximately $1.0 billion 4.75% Senior Notes due 2025 (the
Additional 2025 Notes), $2.5 billion 4.25% Senior Notes due 2027 (the 2027
Notes), and $3.5 billion 4.625% Senior Notes due 2029 (the 2029 Notes). The net
proceeds of the 2027 Notes and the 2029 Notes and a portion of the net proceeds
of the Additional 2025 Notes were used to finance the cash consideration.


                                       50

--------------------------------------------------------------------------------

Table of Contents




In connection with the WellCare Acquisition, in January 2020, we completed an
exchange offer for 5.25% Senior Notes due 2025 and 5.375% Senior Notes due 2026
(collectively, the WellCare Notes) issued by WellCare and issued $1,146 million
aggregate principal amount of 5.25% Senior Notes due 2025 and $747 million
aggregate principal amount of 5.375% Senior Notes due 2026.

Based on our operating plan, we expect that our available cash, cash equivalents
and investments, cash from our operations and cash available under our Company
Credit Facility will be sufficient to finance our general operations and capital
expenditures for at least 12 months from the date of this filing.

                            CONTRACTUAL OBLIGATIONS

The following table summarizes future contractual obligations. These obligations
contain estimates and are subject to revision under a number of circumstances.
Our debt consists of borrowings from our senior notes, Revolving Credit
Facility, Term Loan Facility, mortgages and capital leases. The purchase
obligations consist primarily of software purchases and maintenance contracts.
The contractual obligations and estimated period of payment over the next five
years and beyond are as follows ($ in millions):

                                                   Payments Due by Period
                                             Less Than       1-3        3-5       More Than
                                  Total        1 Year       Years      Years       5 Years
Medical claims liability        $  7,473    $     7,473    $     -    $     -    $         -
Debt and interest                 17,833            669      3,797      2,108         11,259
Lease obligations                  1,176            190        330        218            438
Purchase obligations                 260            132         93         23             12
Other long-term liabilities (1)        -              -          -          -              -
Total                           $ 26,742    $     8,464    $ 4,220    $ 2,349    $    11,709



(1) Our Consolidated Balance Sheet as of December 31, 2019, includes $1,732
million of other long-term liabilities. This consists primarily of long-term
deferred income taxes, liabilities under our deferred compensation plan,
liabilities related to certain undertakings, reserves for uncertain tax
positions and retirement benefit obligations. These liabilities have been
excluded from the table above as the timing and/or amount of any cash payment is
uncertain.

Commitments

As part of the regulatory approval process in connection with the Fidelis Care
Acquisition, we entered into certain undertakings with the New York State
Department of Health. These undertakings contain various commitments by us that
were effective upon completion of the Fidelis Care Acquisition. One of the
undertakings includes a $340 million contribution by us to the State of New York
to be paid over a five-year period for initiatives consistent with our mission
of providing high quality healthcare to vulnerable populations within New York
State. The present value of the contribution to the State of New York,
approximately $328 million, was expensed during 2018, and $136 million has been
paid through 2019.

In addition, in connection with obtaining regulatory approval of the Health Net
acquisition from the California Department of Insurance and the California
Department of Managed Health Care, in 2016 we committed to certain undertakings
(the California Undertakings). The California Undertakings included, among other
items, operational commitments around premiums, dividend restrictions, minimum
Risk Based Capital (RBC) levels, local offices, growth, accreditation, HEDIS
scores and other quality measures, network adequacy, certifications, investments
and capital expenditures. Specifically, we agreed to, among other things:

•      invest an additional $30 million through the California Organized
       Investment Network over the five years following completion of the
       acquisition; of which we have invested $13 million through 2019;


•      build a service center in an economically distressed community in
       California, investing $200 million over 10 years and employing at least
       300 people, of which we have incurred $24 million through 2019;

• contribute $65 million to improve enrollee health outcomes ($10 million

over five years), support locally-based consumer assistance programs ($5

million over five years) and strengthen the healthcare delivery system

($50 million over five years), of which we have contributed $20 million

through 2019, and;

• invest $75 million of its investment portfolio in vehicles supporting

California's healthcare infrastructure, of which we have invested $27
       million through 2019.

The California Undertakings require significant investments by us, may restrict or impose additional material costs on our future obligations and strategic initiatives in certain geographies, and subject us to various enforcement mechanisms.


                                       51

--------------------------------------------------------------------------------


  Table of Contents



                  REGULATORY CAPITAL AND DIVIDEND RESTRICTIONS

Our operations are conducted through our subsidiaries. As managed care
organizations, most of our subsidiaries are subject to state regulations and
other requirements that, among other things, require the maintenance of minimum
levels of statutory capital, as defined by each state, and restrict the timing,
payment and amount of dividends and other distributions that may be paid to
us. Generally, the amount of dividend distributions that may be paid by a
regulated subsidiary without prior approval by state regulatory authorities is
limited based on the entity's level of statutory net income and statutory
capital and surplus.

Our regulated subsidiaries are required to maintain minimum capital requirements
prescribed by various regulatory authorities in each of the states in which we
operate. As of December 31, 2019, our subsidiaries had aggregate statutory
capital and surplus of $8,725 million, compared with the required minimum
aggregate statutory capital and surplus requirements of $3,407 million. During
the year ended December 31, 2019, we received $18 million of net dividends from
our regulated subsidiaries. For our subsidiaries that file with the National
Association of Insurance Commissioners (NAIC), we estimate our RBC percentage to
be in excess of 350% of the Authorized Control Level.

Under the California Knox-Keene Health Care Service Plan Act of 1975, as amended
("Knox-Keene"), certain of our California subsidiaries must comply with tangible
net equity (TNE) requirements. Under these Knox-Keene TNE requirements, actual
net worth less unsecured receivables and intangible assets must be more than the
greater of (i) a fixed minimum amount, (ii) a minimum amount based on premiums
or (iii) a minimum amount based on healthcare expenditures, excluding capitated
amounts. In addition, certain of our California subsidiaries have made certain
undertakings to the DMHC to restrict dividends and loans to affiliates, to the
extent that the payment of such would reduce such entities' TNE below the
required amount as specified in the undertaking.

Under the New York State Department of Health Codes, Rules and Regulations Title
10, Part 98, our New York subsidiary must comply with contingent reserve
requirements.  Under these requirements, net worth based upon admitted assets
must equal or exceed a minimum amount based on annual net premium income.

The NAIC has adopted rules which set minimum risk-based capital requirements for
insurance companies, managed care organizations and other entities bearing risk
for healthcare coverage. As of December 31, 2019, each of our health plans was
in compliance with the risk-based capital requirements enacted in those states.

As a result of the above requirements and other regulatory requirements, certain
of our subsidiaries are subject to restrictions on their ability to make
dividend payments, loans or other transfers of cash to their parent companies.
Such restrictions, unless amended or waived or unless regulatory approval is
granted, limit the use of any cash generated by these subsidiaries to pay our
obligations. The maximum amount of dividends that can be paid by our insurance
company subsidiaries without prior approval of the applicable state insurance
departments is subject to restrictions relating to statutory surplus, statutory
income and unassigned surplus. As of December 31, 2019, the amount of capital
and surplus or net worth that was unavailable for the payment of dividends or
return of capital to us was $3,407 million in the aggregate.

                        RECENT ACCOUNTING PRONOUNCEMENTS

For this information, refer to Note 2. Summary of Significant Accounting Policies, in the Notes to the Consolidated Financial Statements, included herein.


                   CRITICAL ACCOUNTING POLICIES AND ESTIMATES

Our discussion and analysis of our results of operations and liquidity and
capital resources are based on our consolidated financial statements which have
been prepared in accordance with GAAP. Our significant accounting policies are
more fully described in Note 2. Summary of Significant Accounting Policies, to
our consolidated financial statements included elsewhere herein. Our accounting
policies regarding intangible assets, medical claims liability and revenue
recognition are particularly important to the portrayal of our financial
position and results of operations and require the application of significant
judgment by our management. As a result, they are subject to an inherent degree
of uncertainty. We have reviewed these critical accounting policies and related
disclosures with the Audit Committee of our Board of Directors.

                                       52

--------------------------------------------------------------------------------

Table of Contents

Goodwill and Intangible Assets



We have made several acquisitions that have resulted in our recording of
intangible assets. These intangible assets primarily consist of customer
relationships, purchased contract rights, provider contracts, trade names and
goodwill. Key assumptions used in the valuation of these intangible assets
include, but are not limited to, member attrition rates, contract renewal
probabilities, revenue growth rates, expectations of profitability, and discount
and royalty rates. We allocate the fair value of purchase consideration to the
assets acquired and liabilities assumed based on their fair values at the
acquisition date. The excess of the fair value of consideration transferred over
the fair value of the net assets acquired is recorded as goodwill. Goodwill is
generally attributable to the value of the synergies between the combined
companies and the value of the acquired assembled workforce, neither of which
qualifies for recognition as an intangible asset. At December 31, 2019, we had
$6,863 million of goodwill and $2,063 million of other intangible assets.

Intangible assets are amortized using the straight-line method over the
following periods:

    Intangible Asset        Amortization Period
Purchased contract rights      5 - 21 years
Provider contracts             4 - 15 years
Customer relationships         3 - 15 years
Trade names                    7 - 20 years
Developed technologies          2 - 7 years
Other intangibles               2 - 5 years



Our management evaluates whether events or circumstances have occurred that may
affect the estimated useful life or the recoverability of the remaining balance
of goodwill and other identifiable intangible assets. If the events or
circumstances indicate that the remaining balance of the intangible asset or
goodwill may be impaired, the potential impairment will be measured based upon
the difference between the carrying amount of the intangible asset or goodwill
and the fair value of such asset. Our management must make assumptions and
estimates, such as the discount factor, future utility and other internal and
external factors, in determining the estimated fair values. While we believe
these assumptions and estimates are appropriate, other assumptions and estimates
could be applied and might produce significantly different results.

Goodwill is reviewed annually during the fourth quarter for impairment. In
addition, an impairment analysis of intangible assets would be performed based
on other factors. These factors include significant changes in membership,
financial performance, state funding, medical contracts and provider networks
and contracts.

In January 2017, the Financial Accounting Standards Board issued an Accounting
Standards Update (ASU) simplifying the test for goodwill impairment. During the
third quarter of 2019, we adopted the new guidance. The amendments in the ASU
eliminated step 2 from the quantitative goodwill impairment test while still
allowing management to first perform the qualitative assessment to determine if
a quantitative assessment is necessary. If the quantitative assessment is
required, the impairment test under the new ASU is performed by comparing the
fair value of the reporting unit with its carrying amount and recognizing an
impairment charge for the amount by which the carrying amount exceeds the fair
value. The impairment charge under the new ASU is limited to the total amount of
goodwill allocated to that reporting unit. We first assess qualitative factors
to determine if a quantitative impairment test is necessary. We generally do not
calculate the fair value of a reporting unit unless we determine, based on a
qualitative assessment, that it is more likely than not that its fair value is
less than its carrying amount. However, in certain circumstances, such as recent
acquisitions, we may elect to perform a quantitative assessment without first
assessing qualitative factors. During the third quarter of 2019, we recorded
$271 million of non-cash goodwill ($259 million) and intangible asset ($12
million) impairment, substantially all associated with our U.S. Medical
Management (USMM) physician home health business in the Specialty Services
segment. The impairment was identified as part of our quarterly review
procedures, which included an analysis of new information related to its shared
savings demonstration programs, slower than expected penetration of the
physician home health business model into its Medicaid population, and the
related impact to revised forecasts. We utilized the income approach in the
analysis, which derives the fair value of the intangible assets and goodwill
based on the present value of discounted expected cash flows.


                                       53

--------------------------------------------------------------------------------


  Table of Contents


Medical Claims Liability

Our medical claims liability includes claims reported but not yet paid, or
inventory, estimates for claims incurred but not reported, or IBNR, and
estimates for the costs necessary to process unpaid claims at the end of each
period. We estimate our medical claims liability using actuarial methods that
are commonly used by health insurance actuaries and meet Actuarial Standards of
Practice. These actuarial methods consider factors such as historical data for
payment patterns, cost trends, product mix, seasonality, utilization of
healthcare services and other relevant factors.

Actuarial Standards of Practice generally require that the medical claims
liability estimates be adequate to cover obligations under moderately adverse
conditions. Moderately adverse conditions are situations in which the actual
claims are expected to be higher than the otherwise estimated value of such
claims at the time of estimate. The claims amounts ultimately settled will most
likely be different than the estimate that satisfies the Actuarial Standards of
Practice. We include in our IBNR an estimate for medical claims liability under
moderately adverse conditions which represents the risk of adverse deviation of
the estimates in our actuarial method of reserving.

We use our judgment to determine the assumptions to be used in the calculation
of the required estimates. The assumptions we consider when estimating IBNR
include, without limitation, claims receipt and payment experience (and
variations in that experience), changes in membership, provider billing
practices, healthcare service utilization trends, cost trends, product mix,
seasonality, prior authorization of medical services, benefit changes, known
outbreaks of disease or increased incidence of illness such as influenza,
provider contract changes, changes to fee schedules, and the incidence of high
dollar or catastrophic claims.

We apply various estimation methods depending on the claim type and the period
for which claims are being estimated. For more recent periods, incurred
non-inpatient claims are estimated based on historical per member per month
claims experience adjusted for known factors. Incurred hospital inpatient claims
are estimated based on known inpatient utilization data and prior claims
experience adjusted for known factors. For older periods, we utilize an
estimated completion factor based on our historical experience to develop IBNR
estimates. The completion factor is an actuarial estimate of the percentage of
claims that have been received or adjudicated as of the end of a reporting
period relative to the estimate of the total ultimate incurred costs for that
same period. When we commence operations in a new state or region, we have
limited information with which to estimate our medical claims liability. See
"Risk Factors - Failure to accurately estimate and price our medical expenses or
effectively manage our medical costs or related administrative costs could
negatively affect our financial position, results of operations and cash flows."
These approaches are consistently applied to each period presented.

Additionally, we contract with independent actuaries to review our estimates on
a quarterly basis. The independent actuaries provide us with a review letter
that includes the results of their analysis of our medical claims liability. We
do not solely rely on their report to adjust our claims liability. We utilize
their calculation of our claims liability only as additional information,
together with management's judgment, to determine the assumptions to be used in
the calculation of our liability for claims.

Our development of the medical claims liability estimate is a continuous process
which we monitor and refine on a monthly basis as additional claims receipts and
payment information becomes available. As more complete claims information
becomes available, we adjust the amount of the estimates, and include the
changes in estimates in medical costs in the period in which the changes are
identified. In every reporting period, our operating results include the effects
of more completely developed medical claims liability estimates associated with
previously reported periods. We consistently apply our reserving methodology
from period to period. As additional information becomes known to us, we adjust
our actuarial models accordingly to establish medical claims liability
estimates.

The paid and received completion factors, claims per member per month and per
diem cost trend factors are the most significant factors affecting the IBNR
estimate. The following table illustrates the sensitivity of these factors and
the estimated potential impact on our operating results caused by changes in
these factors based on December 31, 2019 data:

                                       54

--------------------------------------------------------------------------------


  Table of Contents


                Completion Factors: (1)                                        Cost Trend Factors: (2)
                                       Increase                                                       Increase
       (Decrease)                    (Decrease) in                  (Decrease)                     (Decrease) in
        Increase                    Medical Claims                   Increase                      Medical Claims
       in Factors                     Liabilities                   in Factors                      Liabilities
                                     (in millions)                                                 (in millions)
                (1.00 )%       $                 430                         (1.00 )%       $                     (112 )
                (0.75 )                          321                         (0.75 )                               (84 )
                (0.50 )                          214                         (0.50 )                               (56 )
                (0.25 )                          107                         (0.25 )                               (28 )
                 0.25                           (106 )                        0.25                                  28
                 0.50                           (212 )                        0.50                                  56
                 0.75                           (317 )                        0.75                                  84
                 1.00                           (421 )                        1.00                                 112
(1) Reflects estimated potential changes in medical claims liability caused by changes in completion factors.
(2) Reflects estimated potential changes in medical claims liability caused by changes in cost trend factors for the
most recent periods.



While we believe our estimates are appropriate, it is possible future events
could require us to make significant adjustments for revisions to these
estimates. For example, a 1% increase or decrease in our estimated medical
claims liability would have affected net earnings by $55 million for the year
ended December 31, 2019, excluding the effect of any return of premium, risk
corridor, or minimum MLR programs. The estimates are based on our historical
experience, terms of existing contracts, our observance of trends in the
industry, information provided by our providers and information available from
other outside sources.

The change in medical claims liability is summarized as follows (in millions):
                                                                 Year Ended December 31,
                                               2019                        2018                       2017
Balance, January 1,                   $             6,831         $             4,286         $             3,929
Less: reinsurance recoverable                          27                          18                           5
Balance, January 1, net                             6,804                       4,268                       3,924
Acquisitions                                           59                       1,204                           -
Less: acquired reinsurance
recoverable                                             -                           8                           -
Incurred related to:
Current year                                       59,539                      46,484                      38,225
Prior years                                          (677 )                      (427 )                      (374 )
Total incurred                                     58,862                      46,057                      37,851

Paid related to:
Current year                                       52,453                      41,161                      34,196
Prior years                                         5,819                       3,556                       3,311
Total paid                                         58,272                      44,717                      37,507
Balance, December 31, net                           7,453                       6,804                       4,268
Plus: reinsurance recoverable                          20                          27                          18
Balance, December 31,                 $             7,473         $             6,831         $             4,286
Days in claims payable (1)                             45                          48                          41

(1) Days in claims payable is a calculation of medical claims liability at the end of the period divided by average expense per calendar day for the fourth quarter of each year.





Medical claims are usually paid within a few months of the member receiving
service from the physician or other healthcare provider. As a result, the
liability generally is described as having a "short-tail," which causes less
than 5% of our medical claims liability as of the end of any given year to be
outstanding the following year. We believe that substantially all the
development of the estimate of medical claims liability as of December 31, 2019
will be known by the end of 2020.


                                       55

--------------------------------------------------------------------------------

Table of Contents




Changes in estimates of incurred claims for prior years are primarily
attributable to reserving under moderately adverse conditions. Additionally, as
a result of minimum HBR and other return of premium programs, approximately $49
million, $25 million and $1 million of the "Incurred related to: Prior years"
was recorded as a reduction to premium revenues in 2019, 2018 and 2017,
respectively. Further, claims processing initiatives yielded increased claim
payment recoveries and coordination of benefits related to prior year dates of
service. Changes in medical utilization and cost trends and the effect of
population health management initiatives may also contribute to changes in
medical claim liability estimates. While we have evidence that population health
management initiatives are effective on a case by case basis, these initiatives
primarily focus on events and behaviors prior to the incurrence of the medical
event and generation of a claim. Accordingly, any change in behavior, leveling
of care, or coordination of treatment occurs prior to claim generation and as a
result, the costs prior to the population health management initiative are not
known by us. Additionally, certain population health management initiatives are
focused on member and provider education with the intent of influencing behavior
to appropriately align the medical services provided with the member's acuity.
In these cases, determining whether the population health management initiative
changed the behavior cannot be determined. Because of the complexity of our
business, the number of states in which we operate, and the volume of claims
that we process, we are unable to practically quantify the impact of these
initiatives on our changes in estimates of IBNR.

The following are examples of population health management initiatives that may
have contributed to the favorable development through lower medical utilization
and cost trends:

• Appropriate leveling of care for neonatal intensive care unit hospital


          admissions, other inpatient hospital admissions, and observation
          admissions, in accordance with InterQual or other criteria.

• Management of our pre-authorization list and more stringent review of


          durable medical equipment and injectibles.


•         Emergency department program designed to collaboratively work with

hospitals to steer non-emergency care away from the costly emergency

department setting (through patient education, on-site alternative

urgent care settings, etc.).

• Increased emphasis on case management and clinical rounding where case

managers are nurses or social workers who are employed by the health

plan to assist selected patients with the coordination of healthcare


          services in order to meet a patient's specific healthcare needs.


•         Incorporation of disease management which is a comprehensive,
          multidisciplinary, collaborative approach to chronic illnesses such as
          asthma.


•         Prenatal and infant health programs utilized in our Start Smart For
          Your Baby outreach service.


Revenue Recognition



Our health plans generate revenues primarily from premiums received from the
states in which we operate health plans, premiums received from our members and
CMS for our Medicare product, and premiums from members of our commercial health
plans. In addition to member premium payments, our Marketplace contracts also
generate revenues from subsidies received from CMS. We generally receive a fixed
premium per member per month pursuant to our contracts and recognize premium
revenues during the period in which we are obligated to provide services to our
members at the amount reasonably estimable. In some instances, our base premiums
are subject to an adjustment, or risk score, based on the acuity of its
membership. Generally, the risk score is determined by the State or CMS
analyzing submissions of processed claims data to determine the acuity of our
membership relative to the entire state's membership. We estimate the amount of
risk adjustment based upon the processed claims data submitted and expected to
be submitted to CMS and record revenues on a risk adjusted basis. Some contracts
allow for additional premiums related to certain supplemental services provided
such as maternity deliveries.

Our contracts with states may require us to maintain a minimum HBR or may
require us to share profits in excess of certain levels. In certain
circumstances, including commercial plans, our plans may be required to return
premium to the state or policyholders in the event profits exceed established
levels. We estimate the effect of these programs and recognize reductions in
revenue in the current period. Other states may require us to meet certain
performance and quality metrics in order to receive additional or full
contractual revenue. For performance-based contracts, we do not recognize
revenue subject to refund until data is sufficient to measure performance.

Revenues are recorded based on membership and eligibility data provided by the
states or CMS, which is adjusted on a monthly basis by the states or CMS for
retroactive additions or deletions to membership data. These eligibility
adjustments are estimated monthly and subsequent adjustments are made in the
period known. We continuously review and update those estimates as new
information becomes available. It is possible that new information could require
us to make additional adjustments, which could be significant, to these
estimates.


                                       56

--------------------------------------------------------------------------------

Table of Contents




Our Medicare Advantage contracts are with CMS. CMS deploys a risk adjustment
model which apportions premiums paid to all health plans according to health
severity and certain demographic factors. The CMS risk adjustment model pays
more for members whose medical history would indicate that they are expected to
have higher medical costs. Under this risk adjustment methodology, CMS
calculates the risk adjusted premium payment using diagnosis data from hospital
inpatient, hospital outpatient, physician treatment settings as well as
prescription drug events. We and the healthcare providers collect, compile and
submit the necessary and available diagnosis data to CMS within prescribed
deadlines. We estimate risk adjustment revenues based upon the diagnosis data
submitted and expected to be submitted to CMS and record revenues on a risk
adjusted basis.

Our specialty services generate revenues under contracts with state and federal
programs, healthcare organizations and other commercial organizations, as well
as from our own subsidiaries. Revenues are recognized when the related services
are provided or as ratably earned over the covered period of services.  For
performance-based measures in our contracts, revenue is recognized as data
sufficient to measure performance is available. We recognize revenue related to
administrative services under the TRICARE government-sponsored managed care
support contract for the DoD's TRICARE program on a straight-line basis over the
option period, when the fees become fixed and determinable. The TRICARE contract
includes various performance-based measures. For each of the measures, an
estimate of the amount that has been earned is made at each interim date, and
revenue is recognized accordingly.

Some states enact premium taxes, similar assessments and provider pass-through
payments, collectively premium taxes, and these taxes are recorded as a separate
component of both revenues and operating expenses. Additionally, our insurance
subsidiaries are subject to the Affordable Care Act annual HIF. The ACA imposed
the HIF in 2014, 2015, 2016 and 2018 and is imposing the HIF in 2020. The HIF
was suspended in 2017 and 2019. If we are able to negotiate reimbursement of
portions of these premium taxes or the HIF, we recognize revenue associated with
the HIF on a straight-line basis when we have binding agreements for such
reimbursements, including the "gross-up" to reflect the HIFs non-tax deductible
nature. Collectively, this revenue is recorded as premium tax and health insurer
fee revenue in the Consolidated Statements of Operations. For certain products,
premium taxes, state assessments and the HIF are not pass-through payments and
are recorded as premium revenue and premium tax expense or health insurer fee
expense in the Consolidated Statements of Operations.

Some states require state directed payments that have minimal risk, but are
administered as a premium adjustment.  These payments are recorded as premium
revenue and medical costs at close to a 100% HBR. We have little visibility to
the timing of these payments until they are paid by the state.

                                       57

--------------------------------------------------------------------------------

Table of Contents

© Edgar Online, source Glimpses